[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20191443T1 - Antitumorska sjedinjenja - Google Patents

Antitumorska sjedinjenja Download PDF

Info

Publication number
HRP20191443T1
HRP20191443T1 HRP20191443T HRP20191443T1 HR P20191443 T1 HRP20191443 T1 HR P20191443T1 HR P20191443 T HRP20191443 T HR P20191443T HR P20191443 T1 HRP20191443 T1 HR P20191443T1
Authority
HR
Croatia
Prior art keywords
compound
cancer
formula
pharmaceutically acceptable
lung cancer
Prior art date
Application number
Other languages
English (en)
Inventor
Marchante María Del Carmen Cuevas
Solloso Andrés Francesch
Barrasa Valentín Martínez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of HRP20191443T1 publication Critical patent/HRP20191443T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (15)

1. Sjedinjenje sa formulom V, ili njegova farmaceutski prihvatljiva sol ili estar:
2. Sjedinjenje sa formulom VI, ili njegova farmaceutski prihvatljiva sol ili estar:
3. Sjedinjenje u skladu sa patentnim zahtjevom 1 ili patentnim zahtjevom 2, gdje je sol odabrana od hidroklorid, hidrobromid, hidrojodid, sulfat, nitrat, fosfat, acetat, trifluoroacetat, maleat, fumarat, citrat, oksalat, sukcinat, tartarat, malat, mandelat, metansulfonat, p-toluensulfonat; natrij, kalij, kalcij, amonij soli; i soli etilendiamina, etanolamina, N,N-dial kilen etanolamina, trietanolamina i baznih aminokiselina.
4. Farmaceutska kompozicija koja sadrži sjedinjenje u skladu sa bilo kojim od patentnih zahtjeva 1 do 3 ili njegovu farmaceutski prihvatljivu sol ili estar i farmaceutski prihvatljiv nosač.
5. Dozni oblik koji obuhvaća farmaceutsku kompoziciju u skladu sa patentnim zahtjevom 4.
6. Sjedinjenje u skladu sa bilo kojim od patentnih zahtjeva 1 do 3 ili njegova farmaceutski prihvatljiva sol ili estar, kompozicija u skladu sa patentnim zahtjevom 4 ili dozni oblik u skladu sa patentnim zahtjevom 5, za primjenu kao lijek.
7. Sjedinjenje u skladu sa bilo kojim od patentnih zahtjeva 1 do 3 ili njegova farmaceutski prihvatljiva sol ili estar, kompozicija u skladu sa patentnim zahtjevom 4 ili dozni oblik u skladu sa patentni zahtjevom 5, za primjenu u liječenju raka.
8. Sjedinjenje, kompozicija ili dozni oblik u skladu sa patentnim zahtjevom 7, gdje je rak odabran od raka pluća uključujući rak pluća malih stanica i rak pluća nemalih stanica, rak debelog crijeva, kolorektalnog raka, raka dojke, raka gušterače, sarkoma, raka jajnika i raka želuca.
9. Sjedinjenje, kompozicija ili dozni oblik u skladu sa patentnim zahtjevom 8, gdje je rak odabran od raka pluća uključujući rak pluća malih stanica i rak pluća nemalih stanica, raka dojke, raka gušterače i kolorektalnog raka.
10. Proces za dobivanje sjedinjenja sa formulom V kao što je definirano u patentnom zahtjevu 1 ili njegove farmaceutski prihvatljive soli ili ekstrakti: koji obuhvaćaju korak reagiranja sjedinjenja sa formulom II sa sjedinjenjem sa formulom III da se dobije sjedinjenje sa formulom IV: gdje: X je -O-; R2 je acetil; R3 je vodik; R4 je -CH2OH.
11. Proces u skladu sa patentnim zahtjevom 10, koji obuhvata dalji korak zamjene cijano grupe u sjedinjenju sa formulom IV sa hidroksi grupom da se dobije sjedinjenje sa formulom V.
12. Proces za dobivanje sjedinjenja sa formulom VI kao što je definirano u patentnom zahtjevu 2 ili njegove farmaceutski prihvatljive soli ili ekstrakta: koji obuhvata korak reagiranja sjedinjenja sa formulom II sa sjedinjenjem sa formulom III da se dobije sjedinjenje sa formulom IV: gdje: X je -O-; R2 je acetil; R3 je vodik; R4 je vodik.
13. Proces u skladu sa patentnim zahtjevom 12, koji obuhvata dalji korak zamjene cijano grupe u sjedinjenju sa formulom IV sa hidroksi grupom da se dobije sjedinjenje sa formulom VI.
14. Komplet koji sadrži terapijski efikasnu količinu sjedinjenja u skladu sa bilo kojim od patentnih zahtjeva 1 do 3 i farmaceutski prihvatljiv nosač.
15. Komplet u skladu sa patentnim zahtjevom 14 koji dalje sadrži uputstva za primjenu sjedinjenja u liječenju raka, i poželjnije raka odabranog od raka pluća, uključujući rak pluća nemalih stanica i rak pluća malih stanica, raka debelog crijeva, kolorektalnog raka, raka dojke, raka gušterače, sarkoma, raka jajnika i raka želuca.
HRP20191443 2017-04-27 2019-08-09 Antitumorska sjedinjenja HRP20191443T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382228 2017-04-27
EP17382497 2017-07-26
EP18382287.3A EP3395820B1 (en) 2017-04-27 2018-04-27 Antitumoral compounds

Publications (1)

Publication Number Publication Date
HRP20191443T1 true HRP20191443T1 (hr) 2019-11-15

Family

ID=62063080

Family Applications (5)

Application Number Title Priority Date Filing Date
HRP20230455TT HRP20230455T1 (hr) 2017-04-27 2018-04-27 Antitumorski spojevi
HRP20231233TT HRP20231233T1 (hr) 2017-04-27 2018-04-27 Antitumorski spojevi
HRP20230433TT HRP20230433T1 (hr) 2017-04-27 2018-04-27 Antitumorski spojevi
HRP20191442 HRP20191442T1 (hr) 2017-04-27 2019-08-09 Antitumorska sjedinjenja
HRP20191443 HRP20191443T1 (hr) 2017-04-27 2019-08-09 Antitumorska sjedinjenja

Family Applications Before (4)

Application Number Title Priority Date Filing Date
HRP20230455TT HRP20230455T1 (hr) 2017-04-27 2018-04-27 Antitumorski spojevi
HRP20231233TT HRP20231233T1 (hr) 2017-04-27 2018-04-27 Antitumorski spojevi
HRP20230433TT HRP20230433T1 (hr) 2017-04-27 2018-04-27 Antitumorski spojevi
HRP20191442 HRP20191442T1 (hr) 2017-04-27 2019-08-09 Antitumorska sjedinjenja

Country Status (38)

Country Link
US (5) US11332480B2 (hr)
EP (5) EP3395821B1 (hr)
JP (5) JP6501947B2 (hr)
KR (3) KR102492283B1 (hr)
CN (4) CN114736219B (hr)
AU (4) AU2018260314C1 (hr)
BR (1) BR112019022282A2 (hr)
CA (1) CA3061518A1 (hr)
CL (1) CL2019003057A1 (hr)
CO (1) CO2019011967A2 (hr)
CY (3) CY1121885T1 (hr)
DK (5) DK4101855T3 (hr)
EC (1) ECSP19083967A (hr)
ES (5) ES2944344T3 (hr)
FI (3) FI4101855T3 (hr)
HK (2) HK1255938B (hr)
HR (5) HRP20230455T1 (hr)
HU (5) HUE046109T2 (hr)
IL (3) IL289963B2 (hr)
JO (1) JOP20190254A1 (hr)
LT (5) LT4101855T (hr)
MA (2) MA44020B1 (hr)
MD (5) MD3395821T2 (hr)
ME (2) ME03467B (hr)
MX (3) MX392829B (hr)
MY (1) MY198004A (hr)
PH (1) PH12019550224A1 (hr)
PL (5) PL4101855T3 (hr)
PT (2) PT3395821T (hr)
RS (5) RS59173B1 (hr)
SG (2) SG11201909841RA (hr)
SI (5) SI3395820T1 (hr)
SM (5) SMT202300169T1 (hr)
TN (2) TN2019000211A1 (hr)
TW (3) TWI807411B (hr)
UY (1) UY37706A (hr)
WO (1) WO2018197663A1 (hr)
ZA (1) ZA201907119B (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190254A1 (ar) * 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
PH12022551216A1 (en) * 2019-11-21 2023-07-17 Pharma Mar Sa Methods of treating small cell lung cancer with lurbinectedin formulations
PE20230785A1 (es) * 2020-04-21 2023-05-11 Pharma Mar Sa Conjugados de anticuerpos de farmacos
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
CN117295499A (zh) 2021-05-19 2023-12-26 法马马有限公司 海鞘素的给药方案
WO2024186263A1 (en) * 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives
WO2025077996A1 (en) 2023-10-09 2025-04-17 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
EP4563149A1 (en) 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3205220A (en) 1961-10-26 1965-09-07 Lilly Co Eli Leurosidine and leurocristine and their production
US4762949A (en) 1979-06-20 1988-08-09 University Of Illinois Foundation Acyl and carbamimidoyl alkanediamines
GB2058047B (en) 1979-07-11 1983-09-21 Asahi Chemical Ind Amides and amidines
FR2461995A1 (fr) 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
US4782135A (en) 1980-09-12 1988-11-01 Board Of Trustees, University Of Illinois Composition of matter and process
US5137870A (en) 1980-09-12 1992-08-11 The Board Of Trustees Of The University Of Illinois Didemnins and nordidemnins
EP0048149B1 (en) 1980-09-12 1983-11-30 University of Illinois Foundation Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4548814A (en) 1980-12-18 1985-10-22 The Board Of Trustees Of The University Of Illinois Composition of matter and process
JPS5922518A (ja) 1982-07-29 1984-02-04 余合住金産業株式会社 洋服タンス
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
AU585936B2 (en) 1984-12-28 1989-06-29 Conpharm A.B. Pharmaceutically active podophyllotoxins
US4644072A (en) 1985-04-12 1987-02-17 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
DE3684868D1 (de) 1985-09-20 1992-05-21 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US4731377A (en) 1986-01-31 1988-03-15 Harbor Branch Oceanographic Institute, Inc. Antitumor cyclic peroxides
AU589282B2 (en) 1986-06-09 1989-10-05 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4737510A (en) 1986-09-30 1988-04-12 The Board Of Trustees Of The University Of Illinois Bioactive metabolites from the caribbean sponge agelas coniferin
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US4847246A (en) 1987-09-11 1989-07-11 Wilson George R Antiviral compositions derived from fireflies and their methods of use
FR2623504B1 (fr) 1987-11-25 1990-03-09 Adir Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
ES2054011T3 (es) 1988-09-05 1994-08-01 Sankyo Co Un proceso para la preparacion de un compuesto, "leualacina".
WO1990005731A1 (en) 1988-11-24 1990-05-31 University Of Queensland Cytotoxic macromolecules
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
US5583160A (en) 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
CA2007507C (en) 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5053559A (en) 1989-12-29 1991-10-01 Oxaco S.A. Cleavage of 1,2,4-trioxanes
KR910014122A (ko) 1990-01-19 1991-08-31 디께다 가즈히꼬 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質S−59917a及びその製造方法
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
GB9212000D0 (en) 1992-06-05 1992-07-15 Univ Madrid Complutense New synthetic antitumoral compound
KR950702994A (ko) 1992-08-12 1995-08-23 로렌스 티. 웰츠 탁솔과 복합된, 단백질 키나제 억제제 및 관련 화합물(protein kinase inhibitors and related compounds combined with taxol)
US5756734A (en) 1992-09-11 1998-05-26 Pharmamar, S.A. Crambescidins: new antiviral and cytotoxic compounds from the sponge crambe crambe
ES2059259B1 (es) 1992-09-22 1995-10-01 Pharma Mar S A Pharmar Procedimiento de obtencion de nuevos areno (e)indoles utiles como intermedios en la sintesis de productos con actividad antitumoral.
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
US6274551B1 (en) 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302044D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Cytotoxic compounds i
GB9302046D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US5569757A (en) 1993-03-30 1996-10-29 Rinehart; Kenneth L. 9-deazaadenosine and its 5'-α-D-glycopyranoside isolated from the cyanobacterium anabaena affinis strain VS-1
GB9308111D0 (en) 1993-04-20 1993-06-02 Pharma Gen S A Active compound from a stonge
US5556777A (en) 1993-09-09 1996-09-17 Pharmamar, S.A. Immunosuppressive pharmaceutical compositions new biological activity from a marine agrobacterium sp.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5514708A (en) 1994-02-18 1996-05-07 Pharmamar, S.A. Cytotoxic metabolites from Myriapora truncata
US5681813A (en) 1994-04-06 1997-10-28 Pharma Mar, S.A. Thiodepsipeptide isolated from a marine actinomycete
ES2100124B1 (es) 1994-08-01 1998-04-01 Pharma Mar Sa Perfeccionamientos introducidos en la p.i. 9401697 por terpeno-quinonas con actividad antitumoral.
US5514705A (en) 1994-09-07 1996-05-07 Pharmamar, S.A. Epidioxymanadic acids A and B
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
GB9422946D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Antineoplastic cyclolignan derivatives
GB9504662D0 (en) 1995-03-08 1995-04-26 Pharma Mar Sa Antitumour isocoumarins
US20010039041A1 (en) 1995-06-07 2001-11-08 Pharma Mar, S.A. Immunosuppressive sesbanimide compositions and methods of treatment using same
US5661175A (en) 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
US5852033A (en) 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US5681847A (en) 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
GB9608010D0 (en) 1996-04-18 1996-06-19 Pharma Mar Sa Trunkamide A
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
ATE245435T1 (de) 1996-10-24 2003-08-15 Univ Illinois Totalsynthese des amino hip analogen von didemnin a
CA2269881A1 (en) 1996-10-24 1998-04-30 The Board Of Trustees Of The University Of Illinois Semi-synthetic studies toward didemnin analogues
GB9622427D0 (en) 1996-10-28 1997-01-08 Pharma Mar Sa Antimalarial drugs
USRE38793E1 (en) 1997-04-15 2005-09-06 Rinehart Kenneth L Spisulosine compounds
US6800661B1 (en) 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
US6028077A (en) 1997-04-15 2000-02-22 Rinehart; Kenneth L. Crambescidin compounds
US6107520A (en) 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
AUPO656597A0 (en) 1997-05-02 1997-05-29 Australian National University, The Preparation of therapeutic compounds
US6030943A (en) 1997-05-07 2000-02-29 Crumb; William J. Dehydrodidemnin B as an L-type calcium channel enhancer
GB9723206D0 (en) 1997-11-03 1998-01-07 Inst Biomar Sa New cytotoxic pyridoacridine alkaloids
GB9727301D0 (en) 1997-12-23 1998-02-25 Inst Biomar Sa Asmarine A and B: New cytotoxic alkaloids
US6420357B1 (en) 1997-12-23 2002-07-16 Instituto Biomar, S.A. Cytotoxic alkaloid derivatives including Asmarine A and B isolated from a sponge
GB9801741D0 (en) 1998-01-27 1998-03-25 Inst Biomar Sa New cytotoxic tris (oxazole)-containing macrolides
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
DE69936845T2 (de) 1998-04-06 2008-05-08 The Board Of Trustees Of The University Of Illinois, Urbana Halbsynthetische ectein-ascidine
US6656948B2 (en) 1998-04-29 2003-12-02 Universidad Complutense De Madrid Cytotoxic compounds: derivatives of the pyrido[2,3,4-kl]acridine ring system
JP2004506401A (ja) 1998-05-05 2004-03-04 ファーマ マー,ソシエダッド アノニマ 付着性海生動物の培養
CN100339375C (zh) * 1998-05-11 2007-09-26 法马马有限公司 海鞘素743的代谢物
GB9810998D0 (en) 1998-05-21 1998-07-22 Univ Madrid Complutense Antitumour 1,5-diazaanthraquinones
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
GB9915069D0 (en) 1999-06-28 1999-08-25 Inst Biomar Sa New indolocarbazole alkaloids from a marine actinomycete
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
AU780417B2 (en) 1999-11-15 2005-03-17 Pharma Mar S.A. Aplidine treatment of cancers
WO2001053299A1 (en) 2000-01-19 2001-07-26 The Trustees Of Columbia University In The City Of New York Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
RU2002124591A (ru) 2000-02-16 2004-01-10 Фарма Мар, С.А. (Es) Окси- и амино-замещенные тетрагидрофурил-производные с противоопухолевой активностью
US20030187075A1 (en) 2000-03-20 2003-10-02 Junichi Tanaka Keith Sponge antitumor compounds
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
ES2272462T3 (es) 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
ATE299146T1 (de) 2000-04-12 2005-07-15 Pharma Mar Sa Ecteinaschidin derivate mit antikrebs wirkung
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
GB0010799D0 (en) 2000-05-04 2000-06-28 Inst Biomar Sa Stolonoxides
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0011927D0 (en) 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
CA2410409A1 (en) 2000-06-06 2001-12-13 Pharma Mar, S.A. Antitumoral compounds
GB0016020D0 (en) 2000-06-29 2000-08-23 Inst Biomar Sa New polyciclic xanthones and their use
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
ATE431349T1 (de) 2000-07-11 2009-05-15 Pharma Mar Sa Variolinderivate als antikrebsmittel
JP4099388B2 (ja) 2000-07-13 2008-06-11 プロリズム,インコーポレイテッド 被治療生物の体内にエネルギーを付与する装置
GB0019117D0 (en) 2000-08-03 2000-09-27 Univ Barcelona Derivatives of variolin B
CZ2003993A3 (cs) 2000-10-12 2004-02-18 Pharma Mar, S. A. Léčivo pro léčení rakoviny podáváním aplidinu nebo analogu aplidinu a protektoru kosterního svalstva
AU9402401A (en) 2000-10-12 2002-04-22 Pharma Mar Sa Treatment of cancers
HK1054192B (en) 2000-10-31 2006-09-08 Pharma Mar, S.A. New formula of KAHALALIDE F
CN100374162C (zh) 2000-11-06 2008-03-12 法马马有限公司 海鞘素-743在制备用于治疗肿瘤的药剂中的应用
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
US20040047807A1 (en) 2001-01-24 2004-03-11 Dominik Meyer Use of neurotoxic substances in producing a medicament for treating joint pains
JP2004521122A (ja) 2001-01-25 2004-07-15 ブリストル−マイヤーズ スクイブ カンパニー エポチロン類似体の非経口製剤
WO2002064843A1 (en) 2001-02-09 2002-08-22 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
GB0105745D0 (en) 2001-03-08 2001-04-25 Pharma Gen S A Immobilisation of ligands
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
GB0116966D0 (en) 2001-07-11 2001-09-05 Pharma Mar Sa Anittumoral compounds
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
AU2002334203C1 (en) 2001-10-19 2008-10-09 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
JP2005509650A (ja) 2001-10-19 2005-04-14 ファルマ・マール・ソシエダード・アノニマ 癌治療における抗腫瘍化合物の改良した使用
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
PT1435991E (pt) 2001-10-19 2009-01-16 Pharma Mar Sa Utilização de aplidina para o tratamento de cancro pancreático
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0217638D0 (en) 2002-07-30 2002-09-11 Pharma Mar Sa Total synthesis of myriaporones
CA2494105C (en) 2002-07-31 2013-04-02 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
GB0218816D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa Antitumoral analogs of lamellarins
US20040033940A1 (en) 2002-08-16 2004-02-19 Pharma Mar, S.A. Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
CA2501089C (en) 2002-10-18 2012-07-17 Pharma Mar, S.A.U. 4-methylhexanoic kahalaide f compound
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0303940D0 (en) 2003-02-20 2003-03-26 Pharma Mar Sau Solid phase synthesis of antitumoral compounds
ES2347959T3 (es) 2003-02-20 2010-11-26 Seattle Genetics, Inc. Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer.
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
CN1761480B (zh) 2003-03-12 2012-09-26 达纳-法伯癌症协会有限公司 用于多发性骨髓瘤的治疗的aplidine
MXPA05009742A (es) 2003-03-12 2006-05-25 Dana Farber Cancer Inst Inc Aplidina para tratamiento de mieloma multiple.
JP2006523214A (ja) 2003-03-21 2006-10-12 ジユーリー,マデレーン・エム タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
GB0314726D0 (en) 2003-06-24 2003-07-30 Inst Biomar Sa New cytotoxic depsipeptides
AU2004263287B2 (en) 2003-07-25 2009-02-12 Novartis Ag Substituted lactams and their use as anti-cancer agents
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
EP1680415B1 (en) 2003-10-09 2008-12-31 Abbott Laboratories Pyrrolidinyl urea derivatives as angiogenesis inhibitors
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DE602004016376D1 (de) 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
DE102004011809A1 (de) 2004-03-11 2005-09-29 Robert Bosch Gmbh Magnetsensoranordnung
GB0408958D0 (en) 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
WO2005118584A2 (en) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
CA2573072A1 (en) 2004-07-09 2006-01-19 Rafael Rosell Costa Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
AU2005288696A1 (en) 2004-09-28 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
US20090117176A1 (en) 2004-10-26 2009-05-07 Pharma Mar, S.A. Sociedad Unipersonal Anticancer Treatments
RU2382647C2 (ru) 2004-10-29 2010-02-27 Фарма Мар С.А., Сосьедад Униперсональ Композиции, содержащие эктинэсайдин и дисахарид
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
WO2006066183A2 (en) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
CN101171236A (zh) 2005-05-03 2008-04-30 马尔药品公司 抗肿瘤的四氢嘧啶
GB0515673D0 (en) 2005-08-01 2005-09-07 Pharma Mar Sa Antitumoral compounds
WO2007014971A2 (es) 2005-08-02 2007-02-08 Pharma Mar, S.A. Genes involucrados en la biosíntesis de tiocoralina y producción heteróloga de la misma
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
GB0523098D0 (en) 2005-11-14 2005-12-21 Pharma Mar Sa Antitumoral compounds
JP2009517403A (ja) 2005-11-25 2009-04-30 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュージャージー Parp−1阻害剤の使用
ES2276629B1 (es) 2005-12-15 2009-04-01 Pharma Mar, S.A. Compuestos antitumorales.
ES2288107B1 (es) 2006-01-27 2008-11-01 Fundacion Imabis Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanita Derivados aciclicos saturados e insaturados de cadena larga de sulfamidas como activadores especificos de receptores ppar-alfa.
PL2029155T3 (pl) 2006-02-28 2016-09-30 Ulepszony sposób leczenia szpiczaka mnogiego
JP2009536956A (ja) 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
UA97369C2 (ru) 2006-06-16 2012-02-10 Фарма Мар, С.А. Противоопухолевые соединения дигидропиран-2-она и фармацевтическая композиция на их основе
WO2009050296A1 (en) 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
AU2008313634A1 (en) 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for ET-743 treatment
NZ584695A (en) 2007-10-19 2011-06-30 Pharma Mar Sa Improved antitumoral treatments using PM02734 and an EGFR tyrosine kinase inhibitor (erlotinib)
ES2406107T3 (es) 2007-12-14 2013-06-05 Pharma Mar S.A. Compuestos antitumorales
MY148651A (en) 2007-12-20 2013-05-15 Pharma Mar Sa Antitumoral compounds
US20100323021A1 (en) 2008-01-30 2010-12-23 Pharma Mar, S.A. Antitumoral treatments
EP2262522A1 (en) 2008-03-07 2010-12-22 Pharma Mar, S.A. Improved antitumoral treatments
RU2010140888A (ru) 2008-03-07 2012-04-20 Фарма Мар, С.А. (Es) Улучшенные противораковые терапии
WO2009140675A2 (en) 2008-05-16 2009-11-19 Pharma Mar, S.A. Combination therapy with an antitumor alkaloid
JP2011520846A (ja) 2008-05-16 2011-07-21 ファルマ・マール・ソシエダード・アノニマ 多発性骨髄腫の治療
BRPI0912294B8 (pt) 2008-05-23 2021-05-25 Wyeth Llc compostos de triazina que inibem p13 quinase e mtor, e composições farmacêuticas dos mesmos
US20110118343A1 (en) 2008-07-03 2011-05-19 Pharma Mar, S. A. Antitumoral Macrolides
BRPI0910810A2 (pt) 2008-07-15 2019-09-24 Genentech Inc conjugados derivados de antraciclina, veículo polimérico, anticorpo, peptídeo ou proteína, veículo t-[cho]m, composições farmacêuticas, métodos de tratamento do câncer ou de distúrbios da proliferação celular, derivado de antraciclina, composto conjugado droga-anticorpo, uso, artigo de manufatura e método de produção de um composto conjugado droga-anticorpo"
KR20110043681A (ko) 2008-07-17 2011-04-27 파르마 마르 에스.에이. 항암 화합물
MX2011006532A (es) 2008-12-19 2011-07-13 Pharma Mar Sa Compuestos anticancerigenos.
WO2010149688A2 (en) 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds
UA112746C2 (uk) 2010-04-27 2016-10-25 Фарма Мар, С.А. Протиракові стероїдні лактони, ненасичені в положенні 7(8)
CN107033164A (zh) * 2010-05-25 2017-08-11 法马马有限公司 制备海鞘素化合物的合成方法
CA2817420C (en) 2010-11-12 2019-09-24 Pharma Mar, S.A. Combination therapy with an antitumor alkaloid
DE102012211024B4 (de) 2012-06-27 2024-10-24 Robert Bosch Gmbh Verfahren zum Betreiben eines Fahrzeuges
JP5922518B2 (ja) 2012-07-20 2016-05-24 浜松ホトニクス株式会社 シンチレータパネル及び放射線検出器
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
SG11201811161YA (en) 2016-07-14 2019-01-30 Pfizer Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
CN114751920B (zh) 2024-06-07
MA44021A (fr) 2019-05-15
HK1255941B (en) 2020-04-29
CY1121884T1 (el) 2020-10-14
MX2019012812A (es) 2020-01-14
TN2019000210A1 (en) 2021-01-07
ME03467B (me) 2020-01-20
CN110621678A (zh) 2019-12-27
TW202202509A (zh) 2022-01-16
ES2741901T3 (es) 2020-02-12
LT4101855T (lt) 2023-08-25
PL3395820T3 (pl) 2019-11-29
PL4101855T3 (pl) 2023-12-27
IL270153B2 (en) 2023-10-01
EP4101855B1 (en) 2023-08-02
MX392601B (es) 2025-03-24
SMT202300169T1 (it) 2023-07-20
CL2019003057A1 (es) 2020-02-21
SI3615544T1 (sl) 2023-07-31
RS59173B1 (sr) 2019-10-31
US20210246146A1 (en) 2021-08-12
RS64686B1 (sr) 2023-11-30
CO2019011967A2 (es) 2020-02-18
US11713325B2 (en) 2023-08-01
HUE046109T2 (hu) 2020-02-28
LT3615544T (lt) 2023-05-10
MA44020B1 (fr) 2019-08-30
MD3395821T2 (ro) 2019-10-31
HRP20230433T1 (hr) 2023-07-07
SMT202300160T1 (it) 2023-07-20
MA44020A (fr) 2018-10-31
MD4101855T2 (ro) 2023-12-31
US11339180B2 (en) 2022-05-24
RS64174B1 (sr) 2023-05-31
EP3395820A1 (en) 2018-10-31
SG10201913300YA (en) 2020-03-30
US11332480B2 (en) 2022-05-17
DK3395820T3 (da) 2019-08-12
US20180312529A1 (en) 2018-11-01
IL289963A (en) 2022-03-01
HUE062032T2 (hu) 2023-09-28
AU2022200250C1 (en) 2022-06-23
HUE062157T2 (hu) 2023-10-28
KR102510975B1 (ko) 2023-03-16
ZA201907119B (en) 2021-07-28
TWI807411B (zh) 2023-07-01
ME03466B (me) 2020-01-20
KR20200012846A (ko) 2020-02-05
EP3615544A1 (en) 2020-03-04
KR20220109495A (ko) 2022-08-04
HK1255938B (en) 2020-04-29
MX2021016058A (es) 2022-02-03
UY37706A (es) 2018-11-30
AU2022201657A1 (en) 2022-03-31
TW202344509A (zh) 2023-11-16
PH12019550224A1 (en) 2020-10-12
KR102491180B1 (ko) 2023-01-20
AU2018260314B2 (en) 2021-12-09
EP3395820B1 (en) 2019-05-15
ES2944344T3 (es) 2023-06-20
AU2018260314C1 (en) 2022-04-21
IL289963B1 (en) 2023-06-01
JP7186723B2 (ja) 2022-12-09
TWI742273B (zh) 2021-10-11
FI4047002T3 (fi) 2023-05-22
MX2021016054A (es) 2022-06-01
TWI875118B (zh) 2025-03-01
JP2020517709A (ja) 2020-06-18
ES2944579T3 (es) 2023-06-22
US20220242883A1 (en) 2022-08-04
SI4047002T1 (sl) 2023-07-31
JP2018188431A (ja) 2018-11-29
HRP20191442T1 (hr) 2019-11-15
AU2022200249C1 (en) 2022-06-23
DK4101855T3 (da) 2023-11-06
SI3395821T1 (sl) 2019-09-30
DK4047002T3 (da) 2023-05-01
FI3615544T3 (fi) 2023-05-23
AU2018260314A1 (en) 2019-10-31
CN114736219A (zh) 2022-07-12
EP3615544B1 (en) 2023-03-22
EP4047002B1 (en) 2023-03-08
EP3615544B9 (en) 2024-01-03
MX392829B (es) 2025-03-24
CN110621678B (zh) 2024-09-20
JP6501946B2 (ja) 2019-04-17
RS64200B1 (sr) 2023-06-30
CY1121885T1 (el) 2020-10-14
DK3395821T3 (da) 2019-08-19
WO2018197663A1 (en) 2018-11-01
JP2022130682A (ja) 2022-09-06
LT4047002T (lt) 2023-05-10
HRP20231233T1 (hr) 2024-01-19
ECSP19083967A (es) 2019-12-27
IL295044B2 (en) 2023-11-01
LT3395820T (lt) 2019-08-12
AU2022200249B1 (en) 2022-02-10
PL3615544T3 (pl) 2023-07-17
FI4101855T3 (fi) 2023-09-22
DK3615544T3 (da) 2023-05-30
PL4047002T3 (pl) 2023-07-24
SI4101855T1 (sl) 2024-03-29
CY1126061T1 (el) 2023-11-15
EP4101855A1 (en) 2022-12-14
PL3395821T3 (pl) 2019-10-31
EP4101855B9 (en) 2024-01-03
IL289963B2 (en) 2023-10-01
TN2019000211A1 (en) 2021-01-07
CN117865987A (zh) 2024-04-12
SI3395820T1 (sl) 2019-09-30
MY198004A (en) 2023-07-25
KR102492283B1 (ko) 2023-01-27
JOP20190254A1 (ar) 2019-10-27
HUE045641T2 (hu) 2020-01-28
JP2023052597A (ja) 2023-04-11
PT3395820T (pt) 2019-08-07
EP3395821B1 (en) 2019-05-15
AU2022200250B1 (en) 2022-02-10
IL270153A (hr) 2019-12-31
US20210070775A1 (en) 2021-03-11
MD3395820T2 (ro) 2019-10-31
ES2960063T3 (es) 2024-02-29
IL295044B1 (en) 2023-07-01
JP7490835B2 (ja) 2024-05-27
JP6501947B2 (ja) 2019-04-17
HRP20230455T1 (hr) 2023-07-21
MA44021B1 (fr) 2019-08-30
BR112019022282A2 (pt) 2020-05-19
JP7422812B2 (ja) 2024-01-26
SG11201909841RA (en) 2019-11-28
RS59174B1 (sr) 2019-10-31
IL270153B1 (en) 2023-06-01
SMT201900448T1 (it) 2019-09-09
JP2018188432A (ja) 2018-11-29
EP3395821A1 (en) 2018-10-31
PT3395821T (pt) 2019-08-27
KR20210126791A (ko) 2021-10-20
MD4047002T2 (ro) 2023-08-31
US10538535B2 (en) 2020-01-21
ES2740073T3 (es) 2020-02-05
CN114736219B (zh) 2024-06-07
SMT201900447T1 (it) 2019-09-09
US20240166666A1 (en) 2024-05-23
MD3615544T2 (ro) 2023-08-31
TW201906850A (zh) 2019-02-16
LT3395821T (lt) 2019-08-12
IL295044A (en) 2022-09-01
EP4047002A1 (en) 2022-08-24
SMT202300343T1 (it) 2023-11-13
HUE063736T2 (hu) 2024-01-28
CN114751920A (zh) 2022-07-15
CA3061518A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
HRP20191443T1 (hr) Antitumorska sjedinjenja
JP2018188432A5 (hr)
JP2018188431A5 (hr)
ES2908224T3 (es) Derivados de dolastatina 10 y auristatinas
HRP20150592T4 (hr) Organoborni esterski spojevi i njihove farmaceutske kompozicije
HRP20250418T1 (hr) Novi derivati metil-kinazolinona
HRP20100166T1 (hr) Postupak za pripremu 2-aminotiazol-5-aromatičnih karboksamida kao inhibitora kinaze
CN109021058B (zh) 具有肿瘤耐药逆转活性的ocotillol型皂苷元衍生物及其制备方法和用途
RU2012140021A (ru) КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ
JP2016513108A5 (ja) 治療用化合物
HRP20230362T1 (hr) Kompozicije koje sadrže triciklične heterorociklične spojeve
JP5976810B2 (ja) 5−置換テトランドリン誘導体、その調製方法及びその使用
CN102786575A (zh) 薯蓣皂苷元-3-位衍生物、制备方法及其用途
JPWO2007023778A1 (ja) 新規抗癌併用薬
JP7681599B2 (ja) 選択的cdk4/6阻害剤のがん治療薬
US20170239266A1 (en) Pharmaceutical compositions for inhibiting angiogenesis comprising plant-derived natural compound
CN106496243B (zh) 异土木香内酯衍生物及其盐在制备治疗肺纤维化药物中的应用
CN104387392B (zh) 制备托法替布的方法
CA3173095A1 (en) Stable heavy isotopes in amide functional groups and uses thereof
BRPI0617730A2 (pt) agente para prevenir ou tratar cáncer do páncreas, cáncer de ovário ou cáncer hepático contendo nova pró-fármaco hidrossolúvel
CA3124412A1 (en) Analogues of pentamidine and uses therefor
JP7657222B2 (ja) 選択的cdk4/6阻害剤のがん治療薬
CN106279138B (zh) 芳杂环类衍生物及其在药物中的应用
CN102757477B (zh) 烯丙基半胱氨酰氨基酸甲酯衍生物及其合成方法和应用
CN111171025B (zh) 靶向eEF2K降解剂的制备及其抗乳腺癌的应用